|1.||Citrome, Leslie: 8 articles (01/2015 - 12/2010)|
|2.||Meng, Xiangyi: 6 articles (01/2015 - 09/2011)|
|3.||Weiden, Peter J: 6 articles (01/2015 - 04/2008)|
|4.||Wolfgang, Curt D: 5 articles (04/2008 - 03/2008)|
|5.||Hochfeld, Marla: 4 articles (03/2014 - 09/2011)|
|6.||Cutler, Andrew J: 4 articles (02/2013 - 04/2008)|
|7.||Potkin, Steven G: 3 articles (02/2013 - 04/2008)|
|8.||Volpi, Simona: 3 articles (02/2010 - 03/2008)|
|9.||Lavedan, Christian: 3 articles (02/2010 - 03/2008)|
|10.||Wong, Bruce J O: 2 articles (10/2015 - 06/2013)|
|1.||Schizophrenia (Dementia Praecox)
08/01/2009 - "The oral formulation has demonstrated efficacy in reducing the symptoms of acute schizophrenia at fixed daily doses ranging from 12 to 24 mg. Data reported for categorical definitions of response using the Positive and Negative Syndrome Scale were limited to one study and specifically to rates of achieving a > or = 20% decrease in the positive subscale from baseline; significantly more patients receiving iloperidone 24 mg/day (72%) than placebo (52%) met this criterion, yielding a NNT of five. "
12/01/2009 - "Iloperidone has been shown to be effective in the treatment of schizophrenia in four short-term (4-6 weeks) and three long-term (52 weeks) studies with over 3000 patients exposed to treatment. "
04/01/2008 - "These trials indicate that iloperidone is effective for the treatment of schizophrenia."
01/01/2012 - "Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials."
04/01/2008 - "Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies."
|2.||Psychotic Disorders (Schizoaffective Disorder)
07/21/1995 - "Iloperidone is currently used in clinical trials for the treatment of psychoses. "
04/01/2002 - "Iloperidone is a novel atypical antipsychotic compound currently under clinical development for the treatment of psychotic disorders. "
01/01/2012 - "Consistent with product labeling, iloperidone 10-16 mg/day or 20-24 mg/day demonstrated significant improvement over placebo on BPRSd and PANSS-T scores, as well as on PANSS-P and PANSS-N subscale scores over 6 weeks of treatment in patients with schizophrenia and in the ITT population, which includes patients with schizoaffective disorder. "
01/01/2012 - "We thus conducted an analysis that assessed key efficacy and tolerability outcomes post hoc from four pooled short-term (4-6 weeks) phase III studies that evaluated iloperidone versus placebo in patients with schizophrenia or schizoaffective disorder. "
01/01/2012 - "Patient-level data were pooled from four prospective, randomized, double-blind, placebo-controlled and active-controlled, multicenter trials of iloperidone in patients with schizophrenia or schizoaffective disorder aged 18-65 years. "
|3.||Psychomotor Agitation (Akathisia)
04/01/2008 - "Overall, there was improvement in akathisia with iloperidone treatment. "
02/01/2014 - "The favorable EPS and akathisia profile of iloperidone makes it an attractive choice for patients whose compliance is limited by these effects. "
05/01/2010 - "Additional information is made available regarding the safety and tolerability of iloperidone, with the FDA acknowledging an overall attractive profile that includes less akathisia and extrapyramidal symptoms than other agents in its class. "
02/01/2013 - "This study further supports the long-term safety and tolerability of iloperidone for the treatment of schizophrenia, including iloperidone's favorable effect on metabolic laboratory parameters and low propensity to cause akathisia or EPS."
01/01/2015 - "The observed outcomes are consistent with what has been previously reported regarding iloperidone's favorable akathisia/EPS profile and modest impact on somnolence/sedation, body weight, and metabolic variables."
11/01/2013 - "Combining iloperidone with idebenone and converting into NLC has contributed in effectively reducing oxidative stress in the brain and helped in reversing the catalepsy induced by repeated iloperidone administration."
09/01/1995 - "Iloperidone was substantially less active in models of extrapyramidal side effect (EPS) liability, such as preventing apomorphine-induced stereotypy and causing catalepsy in rats. "
|1.||Antipsychotic Agents (Antipsychotics)
|2.||Ciliary Neurotrophic Factor (CNTF)
|4.||Risperidone (Risperdal Consta)
|7.||N- (2- (4- (1,2- benzisothiazol- 3- yl)- 1- piperazinylmethyl)- 1- cyclohexylmethyl)- 2,3- bicyclo(2.2.1)heptanedicarboximide
|4.||Drug Therapy (Chemotherapy)